PUBLISHER: IMARC | PRODUCT CODE: 1702088
PUBLISHER: IMARC | PRODUCT CODE: 1702088
The global ophthalmic devices market size reached USD 28.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 39.7 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033. The market is propelled by the expanding geriatric population, rising prevalence of eye ailments, and the growing medical tourism sector which is driving innovation and investment in advanced eye care technologies.
Ophthalmic devices are medical equipment used for surgical diagnosis and vision correction. They comprise contact lenses, contact lens care products, diagnostics, implants, intraocular lenses (IOLs), lasers, phacoemulsification systems, artificial tears, and surgical instruments. They are used to diagnose and cure ocular abnormalities or deficits, and other eye diseases. They aid in making the eye-treatment procedure more convenient for patients and ophthalmologists by reducing treatment time and providing high-quality eye care. At present, due to the rising prevalence of ophthalmic diseases, such as cataracts and glaucoma, there is an increase in the demand for ophthalmic devices across the globe.
The growing reliance on digital devices, such as laptops, smartphones, computers and e-readers, represents one of the key factors driving the market. Moreover, there is a rise in the utilization of intraocular lenses (IOLs) to replace the natural lens of eyes for restoring both near and distant vision. This, along with the expanding healthcare industry, is propelling the growth of the market. In addition, the growing customer training and education among eye care professionals to cure eye diseases and associated complications is positively influencing the market. Besides this, key market players are extensively investing in research and development (R&D) activities for the development of novel devices to treat vision errors. This, coupled with the rising awareness about ophthalmic devices among individuals, is offering lucrative growth opportunities to industry investors. Additionally, there is an increase in the employment of micro-invasive glaucoma (MIGs) surgical implants for the treatment of mild to moderate glaucoma. In line with this, governments of several countries are undertaking initiatives to promote eye health, which is bolstering the market growth.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Carl Zeiss Meditec AG, EssilorLuxottica SA, Haag-Streit Group, HOYA Surgical Optics GmbH (Hoya Corporation), Leica Microsystems GmbH (Danaher Corporation), Nidek Co Ltd., Topcon Corporation, Volk Optical Inc. and Ziemer Ophthalmic Systems AG.